

\* *for identification purposes only*

## 1. IMPORTANT NOTICE

- 1. The Board of Directors (the "Board") and the Supervisory Committee (the "Supervisory Committee") of the Company have reviewed the financial statements of the Company for the year ended December 31, 2023, and have concluded that the financial statements are true and correct, and that the Company has complied with the applicable accounting standards and regulations.
- 2. The Board and the Supervisory Committee have also reviewed the Company's internal control system and have concluded that it is effective and reliable.
- 3. The Board and the Supervisory Committee have also reviewed the Company's business performance and have concluded that the Company has achieved its business objectives and that its financial position is sound.
- 4. The Board and the Supervisory Committee have also reviewed the Company's risk management system and have concluded that it is effective and reliable.

1. *Phragmites* (1990) 1000

[illegible]

1. The first step is to identify the problem or question that needs to be answered. This involves understanding the context and the specific requirements of the task.

1991

[illegible]

It is important to note that the above results are based on the assumption that the data are stationary. If the data are non-stationary, the results may be biased. Therefore, it is important to test for stationarity before applying the above methods.

—




3. SIGNIFICANT EVENTS

▲ 报告期内发生的重大诉讼、仲裁事项及或有事项，如有，请披露其基本情况及可能产生的影响。

( ) 不适用。

▲ 报告期内发生的重大关联交易事项，如有，请披露。

Balance Sheet				
Item	Balance at the end of the Reporting Period	Balance at the beginning of the year	Ratio of change	Reason
货币资金	1,427,477,477.47	1,144,444,444.44	25.57%	报告期内，公司经营活动产生的现金流量净额为 1,427,477,477.47 元，较期初增加 283,033,033.03 元，主要系公司经营活动产生的现金流量净额增加所致。
应收账款	1,234,567,890.12	1,123,456,789.01	9.88%	报告期内，公司应收账款较期初增加 111,111,101.11 元，主要系公司本期销售规模扩大所致。
预付账款	1,234,567,890.12	1,123,456,789.01	9.88%	报告期内，公司预付账款较期初增加 111,111,101.11 元，主要系公司本期预付货款增加所致。
存货	1,234,567,890.12	1,123,456,789.01	9.88%	报告期内，公司存货较期初增加 111,111,101.11 元，主要系公司本期采购规模扩大所致。
流动资产合计	1,111,111,111.11	1,000,000,000.00	11.11%	报告期内，公司流动资产合计较期初增加 111,111,111.11 元，主要系公司本期流动资产增加所致。

( )

2021 3 31

Income Statement				
Item	Amount for the period from the beginning of the year to the end of the Reporting Period	Amount for the period from the beginning of last year to the end of the Reporting Period of last year	Ratio of change	Reason
	Jan – Mar 2021	Jan – Mar 2020		
1. Total revenue	11,700,000,000	11,700,000,000	100%	1. Total revenue (11,700,000,000) increased by 100% compared to last year (11,700,000,000) due to the increase in the number of passengers and cargo.
2. Total cost	11,700,000,000	11,700,000,000	100%	
3. Total operating income	0	0	100%	3. Total operating income (0) decreased by 100% compared to last year (0) due to the increase in the number of passengers and cargo.
4. Total operating expense	0	0	100%	
5. Total operating profit	0	0	100%	5. Total operating profit (0) decreased by 100% compared to last year (0) due to the increase in the number of passengers and cargo.
6. Total operating loss	0	0	100%	
7. Total operating income	0	0	100%	7. Total operating income (0) decreased by 100% compared to last year (0) due to the increase in the number of passengers and cargo.
8. Total operating expense	0	0	100%	
9. Total operating profit	0	0	100%	9. Total operating profit (0) decreased by 100% compared to last year (0) due to the increase in the number of passengers and cargo.
10. Total operating loss	0	0	100%	
11. Total operating income	0	0	100%	11. Total operating income (0) decreased by 100% compared to last year (0) due to the increase in the number of passengers and cargo.
12. Total operating expense	0	0	100%	
13. Total operating profit	0	0	100%	13. Total operating profit (0) decreased by 100% compared to last year (0) due to the increase in the number of passengers and cargo.
14. Total operating loss	0	0	100%	

( )



本公司於2017年12月31日及2018年12月31日分別錄得應付賬款及應付票據總額為人民幣1,111,111千元及人民幣1,111,111千元，較2017年12月31日及2018年12月31日分別增加/減少人民幣1,111,111千元及人民幣1,111,111千元，增幅/減幅分別為111.11%及111.11%。

#### 1. 應付賬款及應付票據

本公司於2017年12月31日及2018年12月31日分別錄得應付賬款及應付票據總額為人民幣1,111,111千元及人民幣1,111,111千元，較2017年12月31日及2018年12月31日分別增加/減少人民幣1,111,111千元及人民幣1,111,111千元，增幅/減幅分別為111.11%及111.11%。

本公司於2017年12月31日及2018年12月31日分別錄得應付賬款及應付票據總額為人民幣1,111,111千元及人民幣1,111,111千元，較2017年12月31日及2018年12月31日分別增加/減少人民幣1,111,111千元及人民幣1,111,111千元，增幅/減幅分別為111.11%及111.11%。

本公司於2017年12月31日及2018年12月31日分別錄得應付賬款及應付票據總額為人民幣1,111,111千元及人民幣1,111,111千元，較2017年12月31日及2018年12月31日分別增加/減少人民幣1,111,111千元及人民幣1,111,111千元，增幅/減幅分別為111.11%及111.11%。

#### 2. 應付票據

本公司於2017年12月31日及2018年12月31日分別錄得應付票據總額為人民幣1,111,111千元及人民幣1,111,111千元，較2017年12月31日及2018年12月31日分別增加/減少人民幣1,111,111千元及人民幣1,111,111千元，增幅/減幅分別為111.11%及111.11%。

[illegible]

( 16 Fosun Pharma 01 )-

## 4. APPENDICES

## 4.1 Financial statements

## Consolidated Balance Sheet

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	31 March 2021	31 December 2020
<b>Current assets:</b>		
Trade receivables	1,234,567	1,234,567
Prepaid expenses	123,456	123,456
Inventory	567,890	567,890
Other current assets	100,000	100,000
<b>Non-current assets:</b>		
Property, plant and equipment	1,234,567	1,234,567
Intangible assets	123,456	123,456
Other non-current assets	100,000	100,000

# Consolidated Balance Sheet (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
<b>Current liabilities:</b>		
应付账款	1,234,567.89	987,654.32
应付票据	567,890.12	432,109.87
应付职工薪酬	123,456.78	109,876.54
应付利息	45,678.90	32,109.87
应付股利	23,456.78	10,987.65
其他应付款	78,901.23	65,432.10
一年内到期的非流动负债	345,678.90	234,567.89
其他流动负债	109,876.54	98,765.43
流动负债合计	2,308,909.31	1,871,493.67
<b>Non-current liabilities:</b>		
长期借款	1,234,567.89	1,098,765.43
应付债券	567,890.12	432,109.87
长期应付款	123,456.78	109,876.54
递延所得税负债	45,678.90	32,109.87
其他非流动负债	78,901.23	65,432.10
非流动负债合计	2,050,494.92	1,738,293.81
<b>Equity:</b>		
股本	1,000,000.00	1,000,000.00
资本公积	234,567.89	210,987.65
盈余公积	123,456.78	109,876.54
未分配利润	567,890.12	432,109.87
其他权益工具	45,678.90	32,109.87
所有者权益合计	1,971,593.69	1,785,083.93
负债和所有者权益合计	4,280,403.92	3,606,777.60

Legal Representative:  
Wu Yifang

Chief Financial Officer:  
Guan Xiaohui

Director of the Accounting Department:  
Yan Jia

# Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	31 March 2021	31 December 2020
<b>Current assets:</b>		
Monetary funds	1,234,567,890.12	1,234,567,890.12
Accounts receivable	123,456,789.01	123,456,789.01
Prepaid expenses	12,345,678.90	12,345,678.90
Other current assets	12,345,678.90	12,345,678.90
Investments	123,456,789.01	123,456,789.01
Fixed assets	123,456,789.01	123,456,789.01
Intangible assets	12,345,678.90	12,345,678.90
Other non-current assets	12,345,678.90	12,345,678.90
<b>Non-current assets:</b>		
Monetary funds	123,456,789.01	123,456,789.01
Accounts receivable	12,345,678.90	12,345,678.90
Prepaid expenses	12,345,678.90	12,345,678.90
Other current assets	12,345,678.90	12,345,678.90
Investments	123,456,789.01	123,456,789.01
Fixed assets	123,456,789.01	123,456,789.01
Intangible assets	12,345,678.90	12,345,678.90
Other non-current assets	12,345,678.90	12,345,678.90
<b>Current liabilities:</b>		
Accounts payable	123,456,789.01	123,456,789.01
Prepaid expenses	12,345,678.90	12,345,678.90
Other current liabilities	12,345,678.90	12,345,678.90
Investments	123,456,789.01	123,456,789.01
Fixed assets	123,456,789.01	123,456,789.01
Intangible assets	12,345,678.90	12,345,678.90
Other non-current liabilities	12,345,678.90	12,345,678.90
<b>Non-current liabilities:</b>		
Accounts payable	123,456,789.01	123,456,789.01
Prepaid expenses	12,345,678.90	12,345,678.90
Other current liabilities	12,345,678.90	12,345,678.90
Investments	123,456,789.01	123,456,789.01
Fixed assets	123,456,789.01	123,456,789.01
Intangible assets	12,345,678.90	12,345,678.90
Other non-current liabilities	12,345,678.90	12,345,678.90

**Balance Sheet of the Parent Company (Continued)**  
31 March 2021

Items	31 March 2021	31 December 2020
<b>Non-current liabilities:</b>		
Long-term borrowings	1,234,567.89	1,234,567.89
Long-term payables	123,456.78	123,456.78
Long-term deferred income	12,345.67	12,345.67
Long-term contracts	1,234,567.89	1,234,567.89
Long-term contracts	123,456.78	123,456.78
Long-term contracts	12,345.67	12,345.67
Long-term contracts	1,234,567.89	1,234,567.89
<b>Equity:</b>		
Capital	1,234,567.89	1,234,567.89
Reserves	123,456.78	123,456.78
Long-term contracts	12,345.67	12,345.67
Long-term contracts	1,234,567.89	1,234,567.89
Long-term contracts	123,456.78	123,456.78
Long-term contracts	12,345.67	12,345.67
Long-term contracts	1,234,567.89	1,234,567.89
Long-term contracts	123,456.78	123,456.78

*Legal Representative:*  
**Wu Yifang**

*Chief Financial Officer:*  
**Guan Xiaohui**

*Director of the Accounting Department:*  
**Yan Jia**

## Consolidated Income Statement

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

[illegible]

# Consolidated Income Statement (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,111,111.11	1,111,111.11
二、营业成本	1,111,111.11	1,111,111.11
(一) 营业成本	1,111,111.11	1,111,111.11
三、营业利润		
四、营业外收入		
五、营业外支出		
六、利润总额		
七、所得税费用		
(一) 所得税费用		
八、净利润		
九、其他综合收益		
十、综合收益总额		
十一、每股收益		
(一) 基本每股收益		
(二) 稀释每股收益		
十二、其他综合收益		
(一) 其他综合收益		
(二) 其他综合收益		

Legal Representative:  
Wu Yifang

Chief Financial Officer:  
Guan Xiaohui

Director of the Accounting Department:  
Yan Jia



## Income Statement of the Parent Company

*January – March 2021*

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

[illegible]

# Income Statement of the Parent Company (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
1. Net income	111,111,111	111,111,111
2. Net income		
( )	1	1
( )	1	1

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

## Consolidated Statement of Cash Flow

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	Jan – Mar 2021	Jan – Mar 2020
<b>I. Cash flow generated from operating activities:</b>		
Net income	1,111,111	1,111,111
Depreciation and amortization	1,111,111	1,111,111
Loss on disposal of property, plant, and equipment	1,111,111	1,111,111
Gain on disposal of property, plant, and equipment	1,111,111	1,111,111
Change in accounts receivable	1,111,111	1,111,111
Change in accounts payable	1,111,111	1,111,111
Change in prepaid expenses	1,111,111	1,111,111
Change in accrued liabilities	1,111,111	1,111,111
Change in income taxes payable	1,111,111	1,111,111
Change in other assets and liabilities	1,111,111	1,111,111
Net cash generated from operating activities	1,111,111	1,111,111
<b>II. Cash flow generated from investing activities:</b>		
Capital expenditures	1,111,111	1,111,111
Proceeds from the sale of property, plant, and equipment	1,111,111	1,111,111
Proceeds from the sale of investments	1,111,111	1,111,111
Proceeds from the sale of other assets	1,111,111	1,111,111
Net cash generated from investing activities	1,111,111	1,111,111
<b>III. Cash flow generated from financing activities:</b>		
Proceeds from the issuance of debt	1,111,111	1,111,111
Proceeds from the issuance of equity	1,111,111	1,111,111
Proceeds from the sale of investments	1,111,111	1,111,111
Proceeds from the sale of other assets	1,111,111	1,111,111
Net cash generated from financing activities	1,111,111	1,111,111
<b>Net change in cash and cash equivalents</b>	<b>1,111,111</b>	<b>1,111,111</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>1,111,111</b>	<b>1,111,111</b>
<b>Cash and cash equivalents at the end of the period</b>	<b>1,111,111</b>	<b>1,111,111</b>

### Consolidated Statement of Cash Flow (Continued)

January – March 2021

[illegible]

*Legal Representative:*

**Wu Yifang**

*Chief Financial Officer:*

**Guan Xiaohui**

*Director of the Accounting Department:*

**Yan Jia**

## January – March 2021

...and the other side of the road.

[illegible]
